Duloxetine hydrochloride
Based on 12 publication(s) in Google Scholar
Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD).
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 136434-34-9
- Formula: C18H20ClNOS
- Molecular Weight:333.88
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Anti-Infection Compound Library
HY-L002
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Antidepressant Compound Library
HY-L108
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Duloxetine hydrochloride
More- Cell. 2025 Nov 26;188(24):6861-6872.e14. [Abstract]
- Autophagy. 2026 Mar 5. [Abstract]
- Phytomedicine. 2025 Sep:145:157039. [Abstract]
- Cell Chem Biol. 2026 Jan 15;33(1):74-90.e19. [Abstract]
- Eur J Pharmacol. 2025 Jun 15:997:177476. [Abstract]
- Pharmacol Rep. 2026 May 28. [Abstract]
- Autism Res. 2022 Jan;15(1):27-41. [Abstract]
- Neurotox Res. 2020 Dec;38(4):859-870. [Abstract]
- Mol Brain. 2025 Apr 4;18(1):29. [Abstract]
- Neurosci Lett. 2022 Mar 16;773:136512. [Abstract]
- Patent. US20250002569A1.
- Università Vita-Salute San Raffaele. 2022 Apr 08. 34.
Customer Validation & Images
-
WB
-
IF
-
IF
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
Biological Activity
Chemical Information
-
CAS No. 136434-34-9
-
Appearance Solid
-
Molecular Weight 333.88
-
Formula C18H20ClNOS
-
Color White to off-white
-
SMILES
CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C3=CC=CS3.[H]Cl
-
Synonyms
(S)-Duloxetine hydrochloride; LY-248686 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Cell
2025 Nov 26;188(24):6861-6872.e14. PMID: 41138730 -
Autophagy
2026 Mar 5. PMID: 41787744
Duloxetine hydrochloride purchased from MedChemExpress. Usage Cited in: Autophagy. 2026 Mar 5. [Abstract]
Duloxetine hydrochloride (Duloxetine Hcl; 10 μM; 15 h) increased LC3-II levels incubated neurons in a nutrient-limited medium (nutrient deprivation, ND).
Duloxetine hydrochloride purchased from MedChemExpress. Usage Cited in: Autophagy. 2026 Mar 5. [Abstract]
Duloxetine hydrochloride (Dulox.; 10 μM; 15 h) showed the average number of LAMP1+ puncta did not change in response to these treatments, we observed a significant swelling of LAMP1+ vesicles in Neuro-2a cells.
Duloxetine hydrochloride purchased from MedChemExpress. Usage Cited in: Autophagy. 2026 Mar 5. [Abstract]
Duloxetine hydrochloride (Dulox.; 10 μM; 15 h) induced enlargement of the lysosome in Neuro-2a cells.
-
Phytomedicine
Huangqi Guizhi Wuwu decoction alleviate Oxaliplatin-Induced Peripheral Neuropathy by adjusting the myelin regeneration. [Abstract]2025 Sep:145:157039. PMID: 40618490 -
Cell Chem Biol
Suppression of pain transmission and behavior by inhibition of peripheral diacylglycerol metabolism. [Abstract]2026 Jan 15;33(1):74-90.e19. PMID: 41544618 -
Eur J Pharmacol
L1CAM mimetic compound duloxetine improves cognitive impairment in 5xFAD mice and protects Aβ1-42-damaged HT22 cells. [Abstract]2025 Jun 15:997:177476. PMID: 40057157 -
Pharmacol Rep
Therapeutic potential of combining mirogabalin with antidepressants in relieving hypersensitivity: evidence from a mouse model of neuropathic pain. [Abstract]2026 May 28. PMID: 42207469 -
Autism Res
Duloxetine ameliorates valproic acid-induced hyperactivity, anxiety-like behavior, and social interaction deficits in zebrafish. [Abstract]2022 Jan;15(1):27-41. PMID: 34605202 -
Neurotox Res
2020 Dec;38(4):859-870. PMID: 32415528
Duloxetine hydrochloride purchased from MedChemExpress. Usage Cited in: Neurotox Res. 2020 Dec;38(4):859-870. [Abstract]
Duloxetine hydrochloride (Duloxetine; 0-100 μM; 24 h) inhibited cell viability in N2a cells (a) and C17.2 cells (b).
Duloxetine hydrochloride purchased from MedChemExpress. Usage Cited in: Neurotox Res. 2020 Dec;38(4):859-870. [Abstract]
Duloxetine hydrochloride (Duloxetine; 0, 12.5, 25, 50, 100 μM; 24 h) inhibited N2a cells and C17.2 cells viability in a dose-dependent manner.
Duloxetine hydrochloride purchased from MedChemExpress. Usage Cited in: Neurotox Res. 2020 Dec;38(4):859-870. [Abstract]
Duloxetine hydrochloride (Duloxetine; 0, 12.5, 25, 50, 100 μM; 24 h) inhibited N2a viability in a dose-dependent manner.
-
Mol Brain
Target oxidative stress-induced disulfidptosis: novel therapeutic avenues in Parkinson's disease. [Abstract]2025 Apr 4;18(1):29. PMID: 40186271 -
Neurosci Lett
Participation of transient receptor potential vanilloid 1 in the analgesic effect of duloxetine for paclitaxel induced peripheral neuropathic pain. [Abstract]2022 Mar 16;773:136512. PMID: 35149198 -
-
Solvent & Solubility
DMSO : ≥ 100 mg/mL (299.51 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 5 mg/mL (14.98 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.49 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.49 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 140 mg/mL (419.31 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Redrobe JP, et al. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology (Berl). 1998 Jul;138(1):1-8. [Content Brief]
[2]. Deecher DC, et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.9951 mL | 14.9754 mL | 29.9509 mL | 74.8772 mL |
| 5 mM | 0.5990 mL | 2.9951 mL | 5.9902 mL | 14.9754 mL | |
| 10 mM | 0.2995 mL | 1.4975 mL | 2.9951 mL | 7.4877 mL | |
| DMSO | 15 mM | 0.1997 mL | 0.9984 mL | 1.9967 mL | 4.9918 mL |
| 20 mM | 0.1498 mL | 0.7488 mL | 1.4975 mL | 3.7439 mL | |
| 25 mM | 0.1198 mL | 0.5990 mL | 1.1980 mL | 2.9951 mL | |
| 30 mM | 0.0998 mL | 0.4992 mL | 0.9984 mL | 2.4959 mL | |
| 40 mM | 0.0749 mL | 0.3744 mL | 0.7488 mL | 1.8719 mL | |
| 50 mM | 0.0599 mL | 0.2995 mL | 0.5990 mL | 1.4975 mL | |
| 60 mM | 0.0499 mL | 0.2496 mL | 0.4992 mL | 1.2480 mL | |
| 80 mM | 0.0374 mL | 0.1872 mL | 0.3744 mL | 0.9360 mL | |
| 100 mM | 0.0300 mL | 0.1498 mL | 0.2995 mL | 0.7488 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Duloxetine hydrochloride Related Classifications
HY-B0161A Related Classifications
Powered by Bioz